LUNG CANCER
June 2009
Current Awareness Bulletin
BEATSON WEST OF SCOTLAND CANCER CENTRE LIBRARY
EDUCATION SUITE, 1053 GT WESTERN RD, G12 0YN
0141 301 7285 kirsty.coltart@ggc.scot.nhs.uk
To:
[Name of recipient]
_________________________________________
[Email address of recipient]
_________________________________________
(Organisation/work email address preferred; please write clearly)
This bulletin contains a selection of material gathered from a search of the evidence base,
and is not intended to be comprehensive. Professional judgement should be exercised when
appraising the material. NHS Greater Glasgow and Clyde libraries take no responsibility for
the wording, content and accuracy of the information supplied, which has been extracted in
good faith from reputable sources. NHSGGC is not responsible for the content of external
internet sites.
The library network prefers to send information by email. Please only provide your address
details if you wish to receive the articles (and future bulletins) by post. Please contact your
library if you wish assistance in setting up an email account.
[Department]
________________________________________
[Site]
________________________________________
[Address]
________________________________________
[Address]
________________________________________
Please indicate below the number of any item you wish to order from this bulletin, and return
this form to your local library. Or contact your local library directly. For library contact details
please visit our website at http://www.nhsggc.org.uk/libraryservices.
It is preferred that
articles are sent to you by email; please only complete your address details if you do not wish
to receive articles/bulletins by email.
Identifying numbers of items requested
Return to the Library (please tick box)
LIBRARY, EDUCATION SUITE
BEATSON WEST OF SCOTLAND CANCER CENTRE
1053 GREAT WESTERN ROAD
GLASGOW, G12 0YN
I agree for_____________________________________________
my details to be held and processed in compliance with the Data Protection Act □
26/06/2008 TM
This document can be made available in other formats on request
_____________________________________________
If you would like to receive additional bulletins, please tick the bulletins you would like to receive (there
is no limit), ensure your name and email details (or address details) are on the front cover, and return to
the library address given above.
A&E
Allied Health Professionals
Alzheimer’s disease
Ambulatory care
Anaesthesia
Asthma
Breast Cancer
Burns/Dermatology/Plastic Surgery
Cancer and the Young Adult
Cancer: Pain
Cancer Supportive Care
Child Protection
Clinical Governance
Clinical Microbiology
Community Child Health
Complaints
Coronary Intensive and High
Dependency Care (Nursing)
Corporate Services (Health & Safety, HR,
Training & Legal)
Day surgery
Dental Care Professionals
Dentistry
Diabetes/Endocrinology
Digestive Diseases
Elderly Care Bulletin (Nursing)
Epilepsy
Guidelines
Gynaecologic Oncology
Head and Neck Cancer
Head Injury
Health Improvement/Public Health
Healthcare Associated Infection
Healthy Heart
IT
Lung Cancer
Medical Photography
Medicine for the Elderly
Mental Health in the community
Multiple Sclerosis
Neonatal Nursing and Midwifery
New Books (all sites & Nursing/Midwifery)
New Nurse
Nursing in the community
Nutrition
Obesity
Ophthalmology
Orthopaedics
Osteoporosis
Paediatric Anaesthesia & Pain
Paediatric Oncology Nursing
Paediatric Physiotherapy
Paediatric Respiratory Medicine
Parkinson’s disease
Patient Safety
Pharmacy
Prevention & Treatment of Alcohol &
Drug Abuse (Nursing)
Rheumatology
Resuscitation
Sarcoma
School Nurses
Speech and Language Therapy
Spinal Injuries
Spiritual Care
Stroke (North Glasgow)
Stroke (South Glasgow)
Training, Education and Management
(Nursing)
How to Access Electronic Articles
Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary
1.
2.
3.
4.
5.
6.
Go to the NHS Scotland eLibrary http://www.elib.scot.nhs.uk
Click on Journals
Type in the journal title and click search.
Click on the appropriate title, and then select the supplier you wish to use.
Put in your Athens password at the “Athens login” link.
Select the correct year, volume, issue and page number for the article you want.
Please note that the journal articles you are accessing may be protected by copyright legislation and there may be a
limit on the number of articles you can download or print from any single issue of a journal. If you obtain a copy via
your local library's document request service, you may be required to complete a copyright declaration form. Consult
your local library with any queries, or for further information see the website of the Copyright Licensing Agency at
www.cla.co.uk."
If you have any questions regarding this or any other library services please contact your
librarian.
Compiled by KIrsty Coltart
NHS Greater Glasgow & Clyde Library Network
Beatson West of Scotland Cancer Centre
Education Suite
1053 Great Western Road
G12 0YN
0141 301 7285 kirsty.coltart@ggc.scot.nhs.uk
Journals received in the Beatson WoS Cancer Centre Library have been scanned for articles under the topics listed
below. I have also included some titles held in other libraries in the Network and a few from OVID databases. Please
use links where provided.
General
1.Avery, E. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
Cancer Treatment Reviews 2009 35(4): 340-344
2.Falkson, C.The Management of Thymoma: A Systematic Review and Practice Guideline.
Journal of Thoracic Oncology. 4(7):911-919, July 2009.
3.Kakimi, K. Active specific immunotherapy and cell-transfer therapy for the treatment of nonsmall cell lung cancer. Lung Cancer 2009 65(1):1-8
4.Mahalingam, D. Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical
Perspective, Current Practices, and Future Development. Current Problems in Cancer 2009
33(2): 73-111
5.Musani, A. Treatment options for malignant pleural effusion. Current Opinion in Pulmonary
Medicine. 15(4):380-387, July 2009.
6.Ou, S. Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine.
May 2009.
16(3):157-171,
7.Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Seminars in Oncology. 36(2
Suppl 1):S52-8, 2009 Apr.
8.Tassinari D. Second-line treatments in non-small cell lung cancer. A systematic review of
literature and metaanalysis of randomized clinical trials. Chest. 135(6):1596-609, 2009 Jun.
Combined Modality Therapies
9.Berghmans, T. A phase III randomised study comparing concomitant radiochemotherapy as
induction versus consolidation treatment in patients with locally advanced unresectable nonsmall cell lung cancer. Lung Cancer 2009 64(2): 187-193
10.Horn, L. A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation
Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of
the Eastern Cooperative Oncology Group. Journal of Thoracic Oncology. 4(4):527-533,
April 2009.
11.Jain, A. A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel,
Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel
and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC).
Journal of Thoracic Oncology. 4(6):722-727, June 2009.
12.Karp DD. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP751,871 in combination with paclitaxel and carboplatin in previously untreated, locally
advanced, or metastatic non-small-cell lung cancer. Journal of Clinical Oncology.
27(15):2516-22, 2009 May 20.
13.Le Pechoux, C. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in
patients with limited-stage small-cell lung cancer in complete remission after chemotherapy
and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01):
a randomised clinical trial. The Lancet Oncology 2009 10(5):467-474
14.Rivera MP. Impact of preoperative chemotherapy on pulmonary function tests in
resectable early-stage non-small cell lung cancer. Chest. 135(6):1588-95, 2009 Jun.
15.Rusthoven KE. Is there a role for consolidative stereotactic body radiation therapy
following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
Acta Oncologica. 48(4):578-83, 2009.
16.Schallier, D. Final Overall Results of a Study with a Novel Triplet Induction Chemotherapy
Regimen (PACCAGE) Followed by Consolidation Radiotherapy in Locally Advanced
Inoperable Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 4(6):728735, June 2009.
Drug Therapy
17.Azim, H. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung
cancer: A systematic overview. Lung Cancer 2009 64(2):194-198
18.Carteni, G. Malignant peritoneal mesothelioma—Results from the International Expanded
Access Program using pemetrexed alone or in combination with a platinum agent. Lung
Cancer 2009 64(2): 211-218
19.Di Maio M. Meta-analysis of single-agent chemotherapy compared with combination
chemotherapy as second-line treatment of advanced non-small-cell lung cancer. Journal of
Clinical Oncology. 27(11):1836-43, 2009 Apr 10.
20.Eckardt JR. Phase II study of picoplatin as second-line therapy for patients with small-cell
lung cancer. Journal of Clinical Oncology. 27(12):2046-51, 2009 Apr 20.
21.Esteban, E. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer
Treatment Reviews 2009 35(4): 364-373
22.Gerena-Lewis, M. A Phase II Trial of Denileukin Diftitox in Patients With Previously
Treated Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology.
32(3):269-273, June 2009.
23.Goss G. Randomized phase II study of gefitinib compared with placebo in chemotherapynaive patients with advanced non-small-cell lung cancer and poor performance status.
Journal of Clinical Oncology. 27(13):2253-60, 2009 May 1.
24.Han, K. First Line Chemotherapy with Weekly Docetaxel and Cisplatin in Elderly Patients
with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study. Journal of Thoracic
Oncology. 4(4):512-517, April 2009.
25.Hasturk, S. Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced
Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology. 32(3):280-285, June
2009.
26.Lara PN Jr. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in
extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG
S0124. Journal of Clinical Oncology. 27(15):2530-5, 2009 May 20.
27.Lee, C. Outcomes with first-line platinum-based combination chemotherapy for malignant
pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 2009 64(3): 308313
28.Lin, C. Phase II Study of Epirubicin in Combination With Weekly Docetaxel for Patients
With Advanced NSCLC Who Have Failed or Relapsed After the Frontline Platinum-Based
Chemotherapy. American Journal of Clinical Oncology. 32(2):169-173, April 2009.
29.Pirker R. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung
cancer (FLEX): an open-label randomised phase III trial. Lancet. 373(9674):1525-31, 2009
May 2.
30.Natale RB. Vandetanib versus gefitinib in patients with advanced non-small-cell lung
cancer: results from a two-part, double-blind, randomized phase ii study. Journal of Clinical
Oncology. 27(15):2523-9, 2009 May 20.
31.Reck, M. Phase II study of oral vinorelbine in combination with carboplatin followed by
consolidation therapy with oral vinorelbine as single-agent in unresectable localized or
metastatic non-small cell lung carcinoma. Lung Cancer 2009 64(3):319-325
32.Socinski, M. A randomized, phase II trial of two dose schedules of
carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals
of Oncology 2009 20(6): 1068-73
33.Smit EF. Randomized phase II and pharmacogenetic study of pemetrexed compared with
pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Journal of Clinical Oncology. 27(12):2038-45, 2009 Apr 20.
34.Sugio, K. Prospective phase II study of gefitinib in non-small cell lung cancer with
epidermal growth factor receptor gene mutations. Lung Cancer 2009 64(3): 314-318
35.Takeda, K. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line
treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial
(JCOG0104). Annals of Oncology 2009 20(5): 835-41
36.Tiseo, M. An expanded access program of erlotinib (Tarceva) in patients with advanced
non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer 2009 64(2):199-206
37.Traynor, A. Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung
Cancer: A Wisconsin Oncology Network Phase II Study. Journal of Thoracic Oncology.
4(4):522-526, April 2009.
38.Vilmar, A. Excision repair cross-complementation group 1 (ERCC1) in platinum-based
treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of
current literature. Lung Cancer 2009 64(2): 131-139
39.West, H. Gemcitabine and pemetrexed administered in rapid sequence as front-line
chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Annals of
Oncology 2009 20(5): 850-56
Pathology, Staging, Polymorphisms & Biomarkers
40.Chansky, K. The International Association for the Study of Lung Cancer Staging Project:
Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung
Cancer. Journal of Thoracic Oncology. 4(7):792-801, July 2009.
41.Creaney, J. Serum and pleural fluid biomarkers for mesothelioma. Current Opinion in
Pulmonary Medicine. 15(4):366-370, July 2009.
42.Detterbeck, F. Anatomy, Biology and Concepts, Pertaining to Lung Cancer Stage
Classification. Journal of Thoracic Oncology. 4(4):437-443, April 2009.
43.Huerta, A. A Clinical Pathway for Diagnosing and Staging Lung Cancer. Clinical
Pulmonary Medicine. 16(3):150-156, May 2009.
44.Imai, H. L-type amino acid transporter 1 expression is a prognostic marker in patients with
surgically resected stage I non-small cell lung cancer. Histopathology. 54(7):804-813, June
2009.
45.Liao WT. Centromere protein H is a novel prognostic marker for human nonsmall cell lung
cancer progression and overall patient survival. Cancer. 115(7):1507-17, 2009 Apr 1.
46.Medford, A. Mediastinal staging procedures in lung cancer: EBUS, TBNA and
mediastinoscopy. Current Opinion in Pulmonary Medicine. 15(4):334-342, July 2009.
47.Park, EA. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis:
Investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung
Cancer 2009 64(2): 179-186
48.Pegna, A. Lung cancer screening update. Current Opinion in Pulmonary Medicine.
15(4):327-333, July 2009.
49.Pfeiffer M. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung
cancer. British Journal of Cancer. 100(12):1949-56, 2009 Jun 16.
Prognosis, Survival & Risk Factors
50.Dehing-Oberije, C. Development and External Validation of Prognostic Model for 2-Year
Survival of Non–Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy.
International Journal of Radiation Oncology*Biology*Physics 2009 74(2): 355-362
51.Erridge, S. Improved survival from lung cancer in British Columbia compared to
Scotland—Are different treatment rates the whole story? Lung Cancer 2009 64(3): 358-66
52.Foster NR. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled
analysis of North Central Cancer Treatment Group trials. Cancer. 115(12):2721-31, 2009 Jun
15.
53.Groth, S. Impact of preoperative smoking status on postoperative complication rates and
pulmonary function test results 1-year following pulmonary resection for non-small cell lung
cancer. Lung Cancer 2009 64(3): 352-357
54.Jae Park M. Prognostic model to predict outcomes in nonsmall cell lung cancer patients
treated with gefitinib as a salvage treatment. Cancer. 115(7):1518-30, 2009 Apr 1.
55.Kotta, K. Association between incremental gains in the objective response rate and
survival improvement in phase III trials of first-line chemotherapy for extensive disease smallcell lung cancer. Annals of Oncology 2009 20(5): 829-34
56.Kumar, S. Prognostic implications of circulating anti-p53 antibodies in lung cancer - a
review. European Journal of Cancer Care 2009 18(3): 248-54
57.Lilenbaum, R. Single-Agent Versus Combination Chemotherapy in Patients with Advanced
Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and
Treatment Selection Based on Two Large Randomized Clinical Trials. Journal of Thoracic
Oncology. 4(7):869-874, July 2009.
58.Newlin, H. Unresectable Squamous Cell Carcinoma of the Lung: An Outcomes Study.
International Journal of Radiation Oncology*Biology*Physics 2009 74(2): 370-376
59.Nyman, J. How to improve loco-regional control in stages IIIa–b NSCLC? Results of a
three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 2009
65(1): 62-67
Radiotherapy & Imaging
60.Dooms, C. Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and
Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small
Cell Lung Cancer. Journal of Thoracic Oncology. 4(7):822-828, July 2009.
61.Fenwick, J. Escalation and Intensification of Radiotherapy for Stage III Non-small Cell
Lung Cancer: Opportunities for Treatment Improvement. Clinical Oncology 2009 21(4): 343360
62.Fox, J. Quantification of Tumor Volume Changes During Radiotherapy for Non–Small-Cell
Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2009 74(2):
341-348
63.Guckenberger, M. Dose–Response Relationship for Image-Guided Stereotactic Body
Radiotherapy of Pulmonary Tumors: Relevance of 4D Dose Calculation. International Journal
of Radiation Oncology*Biology*Physics 2009 74(1): 47-54
64.Hoogeman, M. Clinical Accuracy of the Respiratory Tumor Tracking System of the
CyberKnife: Assessment by Analysis of Log Files. International Journal of Radiation
Oncology*Biology*Physics 2009 74(1): 297-303
65.Kawase, T. Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated
Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions. International Journal of
Radiation Oncology*Biology*Physics 2009 74(2): 349-354
66.Kepka, L. Dose-per-Fraction Escalation of Accelerated Hypofractionated ThreeDimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer.
Journal of Thoracic Oncology. 4(7):853-861, July 2009.
67.Koukourakis, M. Computed Tomography Assessment of Lung Density in Patients With
Lung Cancer Treated With Accelerated Hypofractionated Radio-Chemotherapy Supported
With Amifostine. American Journal of Clinical Oncology. 32(3):258-261, June 2009.
68.Lee, D. Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG
PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer. Journal of
Thoracic Oncology. 4(7):816-821, July 2009.
69.Macpherson RE. Non-small-cell lung cancer dimensions: CT-pathological correlation and
interobserver variation. British Journal of Radiology. 82(977):421-5, 2009 May.
70.Stephans, K. Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After
Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable
Patients. Journal of Thoracic Oncology. 4(7):838-844, July 2009.
71.Subedi, N. The clinical impact of integrated FDG PET–CT on management decisions in
patients with lung cancer. Lung Cancer 2009 64(3): 301-307
72.Takeda, A. Dose Distribution Analysis in Stereotactic Body Radiotherapy Using Dynamic
Conformal Multiple Arc Therapy. International Journal of Radiation Oncology*Biology*Physics
2009 74(2): 363-369
73.Wang, L. Time to Treatment in Patients With Stage III Non–Small Cell Lung Cancer.
International Journal of Radiation Oncology*Biology*Physics 2009 74(3): 790-795
Supportive Care & Symptom Management
74.Arrieta, O. High Frequency of Radiation Pneumonitis in Patients with Locally Advanced
Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine after
Induction with Gemcitabine and Carboplatin. Journal of Thoracic Oncology.
July 2009.
4(7):845-852,
75.Bottorff JL. Continued family smoking after lung cancer diagnosis: the patient's
perspective. Oncology Nursing Forum. Online. 36(3):E126-32, 2009 May.
76.Buckholtz, G. Nonpharmacological management of dyspnea. Current Opinion in
Supportive and Palliative Care 2009 3(2): 98-102
77.Currow, D. Advances in the pharmacological management of breathlessness. Current
Opinion in Supportive and Palliative Care 2009 3(2): 103-106
78.Faria, S. The Challenge of Scoring Radiation-induced Lung Toxicity. Clinical Oncology
2009 21(5): 371-375
79.Freedman, O. The role of palliative care in the lung cancer patient: can we improve quality
while limiting futile care?. Current Opinion in Pulmonary Medicine. 15(4):321-326, July
2009.
80.Gilman, S. Physiologic changes and clinical correlates of advanced dyspnea. Current
Opinion in Supportive and Palliative Care 2009 3(2): 93-97
81.Habraken JM. Health-related quality of life in end-stage COPD and lung cancer patients.
Journal of Pain & Symptom Management. 37(6):973-81, 2009 Jun.
82.Hirose T. Patient willingness to undergo chemotherapy and thoracic radiotherapy for
locally advanced non-small cell lung cancer. Psycho-Oncology. 18(5):483-9, 2009 May.
83.Huskamp, H. Discussions With Physicians About Hospice Among Patients With Metastatic
Lung Cancer. Archives of Internal Medicine. 169(10):954-962, May 25, 2009.
84.Kristensen, C. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for
malignant pleural mesothelioma. Radiotherapy and Oncology 2009 92(1): 96-99
85.Ma, J. Association Between RT-Induced Changes in Lung Tissue Density and Global Lung
Function. International Journal of Radiation Oncology*Biology*Physics 2009 74(3): 781-789
86.Peddle CJ. Correlates of adherence to supervised exercise in patients awaiting surgical
removal of malignant lung lesions: results of a pilot study. Oncology Nursing Forum. Online.
36(3):287-95, 2009 May.
87.Rose, J. Systematic review of dose–volume parameters in the prediction of esophagitis in
thoracic radiotherapy. Radiotherapy and Oncology 2009 91(3): 282-287
88.Sachs, S. Pulmonary rehabilitation for dyspnea in the palliative-care setting. Current
Opinion in Supportive and Palliative Care 2009 3(2): 112-19
Surgery
89.Mathew, J. Lung Cancer and Lung Transplantation: A Review. Journal of Thoracic
Oncology. 4(6):753-760, June 2009.
90.Vandenbroucke, E. What is the role for surgery in patients with stage III non-small cell lung
cancer?. Current Opinion in Pulmonary Medicine. 15(4):295-302, July 2009.
91.Yan TD. Systematic review and meta-analysis of randomized and nonrandomized trials
on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-smallcell lung cancer. Journal of Clinical Oncology. 27(15):2553-62, 2009 May 20.